Phase I trial: CD19-Targeted CAR T-Cells in Patients with Residual CLL Following Initial Purine Analog-Based Therapy

Autologous T-cells genetically modified to express CD19-targeted 19-28z chimeric antigen receptors (CARs) induce clinically meaningful responses in a subset of patients with relapsed/refractory CLL. Greater disease burden at CAR T-cell infusion may limit efficacy.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Mark Geyer, Jae Park, Isabelle Rivi ère, Brigitte Senechal, Meier Hsu, Xiuyan Wang, Terence Purdon, Michel Sadelain, Renier Brentjens Source Type: research